Blog

Elvina Almuradova: What Comes After CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer?

Elvina Almuradova/X

Jun 23, 2025, 18:55

Elvina Almuradova: What Comes After CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer?

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:

“What comes after CDK4/6 inhibitors in HR+ metastatic breast cancer?

This ASCO Educational Book chapter comprehensively outlines:

Resistance pathways (ESR1, PIK3CA, AKT/PTEN, RB1…)

Role of genomic profiling in treatment selection

Emerging agents: oral SERDs, CDK2 inhibitors, mutant-selective PI3Kα inhibitors

ADCs (T-DXd, SG, Dato-DXd) reshaping late-line care

Personalized, biomarker-informed care is redefining standards in HR+/HER2– MBC.”

Title: After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer

Authors: Jimmitti Teysir, Maxwell Lloyd, Samer Alkassis, Rena Callahan, Ricki Fairley, Seth Wander, Aditya Bardia, Komal Jhaveri

You can read the Full Article on American Society of Clinical Oncology Educational Book

Elvina Almuradova: What Comes After CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer?

More posts featuring Breast Cancer.

Aditya Bardia Breast Cancer cancer Elvina Almuradova Jimmitti Teysir Komal Jhaveri Maxwell Lloyd metastatic breast cancer OncoDaily Oncology Rena Callahan Ricki Fairley Samer Alkassis Seth Wander

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself